Vanguard Group
KYMR icon

Vanguard Group’s Kymera Therapeutics KYMR Stock Holding History

Vanguard Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$488M Buy
6,267,644
+845,922
+16% +$57.1M 0.01% 1076
2025
Q3 		$307M Sell
5,421,722
-198,126
-4% -$8.94M ﹤0.01% 1317
2025
Q2 		$245M Buy
5,619,848
+388,456
+7% +$13.4M ﹤0.01% 1413
2025
Q1 		$143M Buy
5,231,392
+344,080
+7% +$12.5M ﹤0.01% 1633
2024
Q4 		$197M Buy
4,887,312
+133,546
+3% +$6.03M ﹤0.01% 1548
2024
Q3 		$225M Sell
4,753,766
-68,650
-1% -$3.03M ﹤0.01% 1485
2024
Q2 		$144M Buy
4,822,416
+55,366
+1% +$1.92M ﹤0.01% 1667
2024
Q1 		$192M Buy
4,767,050
+769,486
+19% +$27.5M ﹤0.01% 1548
2023
Q4 		$102M Buy
3,997,564
+72,351
+2% +$1.29M ﹤0.01% 1857
2023
Q3 		$54.6M Buy
3,925,213
+182,125
+5% +$3.66M ﹤0.01% 2088
2023
Q2 		$86.1M Buy
3,743,088
+9,163
+0.2% +$263K ﹤0.01% 1933
2023
Q1 		$111M Buy
3,733,925
+73,618
+2% +$2.37M ﹤0.01% 1783
2022
Q4 		$91.4M Buy
3,660,307
+797,130
+28% +$21.3M ﹤0.01% 1848
2022
Q3 		$62.3M Sell
2,863,177
-11,547
-0.4% -$304K ﹤0.01% 2075
2022
Q2 		$56.6M Buy
2,874,724
+36,999
+1% +$864K ﹤0.01% 2140
2022
Q1 		$120M Sell
2,837,725
-119,449
-4% -$5.04M ﹤0.01% 1840
2021
Q4 		$188M Buy
2,957,174
+55,600
+2% +$3.24M ﹤0.01% 1650
2021
Q3 		$170M Buy
2,901,574
+857,350
+42% +$49.7M ﹤0.01% 1697
2021
Q2 		$99.1M Buy
2,044,224
+311,879
+18% +$13.5M ﹤0.01% 2007
2021
Q1 		$67.3M Buy
1,732,345
+1,109,285
+178% +$66.8M ﹤0.01% 2147
2020
Q4 		$38.6M Buy
623,060
+157,010
+34% +$7.66M ﹤0.01% 2331
2020
Q3 		$15.1M Buy
+466,050
New +$14.2M ﹤0.01% 2587

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group's KYMR Position: Q4 2025 in Review

Vanguard Group increased its Kymera Therapeutics (KYMR) stake by 16% in Q4 2025, buying an estimated $57.1M and bringing the position to 6,267,644 shares worth $488M. The position accounts for 0.01% of the portfolio, ranked #1076.

Vanguard Group first reported a position in KYMR in Q3 2020 and has held it in 22 quarters since. 254 funds tracked by Wall St. Rank hold KYMR as of Q4 2025.

  • Vanguard Group held 6,267,644 shares of Kymera Therapeutics worth $488M as of Q4 2025.
  • Vanguard Group bought 845,922 Kymera Therapeutics shares in Q4 2025, an estimated $57.1M.
  • Kymera Therapeutics made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #1076 holding.
  • Vanguard Group first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • 254 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.